Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22

Rhea-AI Filing Summary

Lyell Immunopharma director Elizabeth G. Nabel received a grant of stock options covering 9,250 shares of common stock. The options have an exercise price of $13.22 per share and were awarded as a compensation grant, not an open-market purchase or sale.

The options vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting), or the first anniversary of June 10, 2026, provided she continues serving as a director. The options expire on June 9, 2036, and following this grant she holds options to acquire 9,250 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider NABEL ELIZABETH G

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	9,250	$0.00	--

Holdings After Transaction: Option (right to buy) — 9,250 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 9,250 options Exercise price: $13.22 per share Underlying shares: 9,250 shares +3 more

6 metrics

Options granted 9,250 options Grant to director Elizabeth G. Nabel

Exercise price $13.22 per share Option grant exercise price

Underlying shares 9,250 shares Common stock underlying the options

Options after grant 9,250 options Total derivative holdings following transaction

Grant date reference June 10, 2026 Date used for vesting conditions

Expiration date June 9, 2036 Option expiration

Key Terms

Option (right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Option (right to buy) financial

"security_title: Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 13.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"The option shares shall vest on the earlier of (a) the date of the next annual meeting..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NABEL ELIZABETH G

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY, SUITE 101

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$13.22	06/10/2026		A		9,250		(1)	06/09/2036	Common Stock	9,250	$0	9,250	D

Explanation of Responses:

1. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

	/s/ Mark Meltz, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Lyell Immunopharma (LYEL) director Elizabeth Nabel report in this Form 4?

Director Elizabeth G. Nabel reported receiving a grant of options for 9,250 shares of Lyell Immunopharma common stock. These options were granted as compensation, not purchased in the open market, and give her the right to buy shares at a fixed exercise price.

How many Lyell Immunopharma (LYEL) options did Elizabeth Nabel receive and at what exercise price?

Elizabeth G. Nabel received options covering 9,250 shares of Lyell Immunopharma common stock. The options carry an exercise price of $13.22 per share, meaning she can buy the underlying shares at that price once the options have vested.

When do Elizabeth Nabel’s Lyell Immunopharma (LYEL) stock options vest?

The option shares vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of June 10, 2026. Vesting is contingent on her providing continuous service as a director through the applicable vesting date.

When do the Lyell Immunopharma (LYEL) options granted to Elizabeth Nabel expire?

The options granted to Elizabeth G. Nabel expire on June 9, 2036. After that expiration date, any unexercised options will lapse, and she will no longer have the right to purchase Lyell Immunopharma common stock under this particular grant.

Is Elizabeth Nabel’s Lyell Immunopharma (LYEL) Form 4 transaction a stock purchase or sale?

The Form 4 reports an option grant, not a purchase or sale of common shares. It is classified as a grant, award, or other acquisition of derivative securities, providing potential future ownership if the options are exercised after vesting.